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Abstract
Objective: Studies have demonstrated verbal memory deficits associated with past
year ecstasy use, although specific underlying components of these deficits are
less understood. Further, prior research suggests potential gender differences in
ecstasy-induced serotonergic changes. Therefore, the current study investigated
whether gender moderated the relationship between ecstasy exposure and
components of verbal memory after controlling for polydrug use and confounding
variables.
Method: Data were collected from 65 polydrug users with a wide range of ecstasy
exposure (ages 18–35; 48 ecstasy and 17 marijuana users; 0–2310 ecstasy
tablets). Participants completed a verbal learning and memory task, psychological
questionnaires, and a drug use interview.
Results: Increased past year ecstasy exposure predicted poorer short and long
delayed free and cued recalls, retention, and recall discrimination. Male ecstasy
users were more susceptible to dose-dependent deficits in retention than female
users.
Conclusion: Past year ecstasy consumption was associated with verbal memory
retrieval, retention, and discrimination deficits in a dose-dependent manner in a
sample of healthy young adult polydrug users. Male ecstasy users were at
particular risk for deficits in retention following a long delay. Gender difference may
be reflective of different patterns of polydrug use as well as increased hippocampal
sensitivity. Future research examining neuronal correlates of verbal memory deficits
in ecstasy users are needed.
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Ecstasy (containing 3,4-methylenedioxymethamphetamine, or MDMA) is a
popular recreational drug among adolescents and young adults Among 10
th and
12
th graders, the Monitoring the Future Study reports slightly increased rates of
use in 2013 versus prior years, at 3.6% and 4%, respectively [1]. According to the
Substance Abuse and Mental Health Services Administration (SAMSHA), the
average age of first use for ecstasy is post-high school, at 19.4 years old [2]. In
addition, individuals who use ecstasy are often polydrug users; in a sample of
nearly 9000 people 18–29 years old, Keyes and colleagues [3] reported that nearly
half of those currently using ecstasy were also using more than 3 other types of
illicit drugs. As such, polydrug use in addition to cumulative ecstasy use (e.g.,
new-onset use and continued use thereafter) is an important consideration in the
present study. Further, ecstasy consumption has been associated with serotonin
(5-HT) release and reuptake and, to a lesser extent, dopamine and norepinephrine
[4–6].
Of particular concern, animal models have suggested that ecstasy acts as
selective serotonergic neurotoxin in several areas of the brain [7–10]. In humans,
neuroimaging studies using positron emission tomography (PET) scans have
shown reduced 5-HT transporter (SERT) densities as well as increased 5-HT 2A
receptor binding, even among abstinent ecstasy users in several cortical regions,
including the hippocampus, frontal, occipital, and temporal areas of the cortex
[11–14]. Such findings suggest damage to the serotonergic system even with
moderate levels of ecstasy use, such that SERT downregulates while 5-HT 2A
upregulates [15]. In addition, a dose-dependent relationship between decreased
SERT densities and increased lifetime ecstasy use has been reported [16]. It has
been suggested that the hippocampus may be particularly sensitive to ecstasy-
associated neurotoxicity [17–20]. Among rats given MDMA, serotonin neuro-
toxicity was greater in the hippocampus than in other brain regions surrounding
the temporal lobe, such as the neocortex and parietal lobe [21–22]. Consistent
with this finding in animals, adolescent ecstasy users demonstrated abnormal
hippocampal activation to a verbal working memory fMRI task [23]. Additionally,
Daumann and colleagues [24] examined brain activation during an fMRI task
among adult abstinent ecstasy users (mean age 527 years) and noted abnormal
activation patterns in frontal and temporal regions among those with histories of
heavy use versus those with moderate use and nonusers.
Given the potential vulnerability of the hippocampus to ecstasy neurotoxicity,
verbal memory functioning in ecstasy users is of great interest. Two meta-analyses
suggest that, in comparison to ecstasy-nai ¨ve controls, ecstasy users demonstrate
learning and memory deficits of magnitudes associated with medium (Cohen’s
d520.55) [25] to large (Cohen’s d520.92) [26] effect sizes. Although these
meta-analyses could have been influenced by the positive publication bias [27], it
is noteworthy that with few exceptions [28–30], individual neuropsychological
studies have suggested that ecstasy is most consistently associated with verbal
learning and memory abnormalities, among former as well as recent, currently
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underlying components of verbal memory have reported deficits in immediate
memory [38–42], delayed memory [19,39,41–43], intrusions and repetitions
[38], and recognition [41–42]. A recent study by Bosch and colleagues [44]
examined brain glucose metabolism and verbal memory in a sample of emerging
adult male ecstasy users and controls (mean age 523.8 years). Among users,
results indicated correlations between prefrontal and parietal hypometabolism
and learning and recall deficits, and between mediotemporal hypometabolism and
recognition deficits. With respect to performance on a prose recall task, there has
been an inability to replicate the deficits found among ecstasy users in Morgan
et al.’s [45] sample [34,46–47].
Consistent with differences in the developmental trajectory of specific brain
regions between men and women, particularly the hippocampus [48–52], it may
be possible that gender moderates the effects of ecstasy on memory. Furthermore,
gender differences in underlying 5HT functioning have been reported. For
example, low cerebral spinal fluid 5HIAA (5-hydroxyindoleacetic acid; a serotonin
metabolite considered as a measurement of serotonin turnover) has been
associated with increased risk for serotonin-related diseases [53–54]. Some studies
have reported that levels of the serotonin metabolite differ as a function of gender
and genetic interactions, with one mechanism being the effect of estrogen on
signal transduction and gene expression affecting serotonin functioning [55–58].
Allott and Redman [59] reviewed the role of gender in ecstasy effects and
concluded that female users appear more vulnerable to variability in 5-HT
functioning as well as to short term dose-dependent psychological and physical
symptoms, while male users tend to show increased acute physiological effects.
However, not all studies examined differences in dose between genders, and few
neurocognitive studies have examined potential gender differences. Reneman et al.
[60] reported greater reductions in SERT binding among female compared to
male ecstasy users, after controlling for verbal intelligence, age, comorbid alcohol,
nicotine and marijuana use, and premorbid Axis I psychiatric disorders. Of note,
this study examined ecstasy dose between moderate- and heavy-using groups of
men and women, finding that men within the heavy-using group reported
increased exposure as compared to heavy-using women as measured by both
number of tablets as well as dosage (tablets/weight ratios). In contrast, Bolla et al.
[61] found that male ecstasy users demonstrated increased dose-dependent
deficits on verbal and visual memory than female users.
The goal of the present study was to examine whether ecstasy use and gender
interact in predicting components of verbal memory including immediate recall,
proactive interference, short delayed recall, long delayed recall, discriminability,
and retention after controlling for important demographic variables such as
ethnicity, premorbid verbal ability, and family history of substance use disorders
(SUD; which have been linked to neurocognitive abnormalities and increased risk
for substance use disorders) [62–63]. Additionally, given that ecstasy users are
typically polydrug users, the authors also sought to account for this issue through
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as well as by controlling for polydrug use in the analyses.
Methods
Participants and Procedure
The Institutional Review Board at the University of Cincinnati approved this
study and its parts. As part of a larger study (see Medina, et al. [20] for detailed
methodological information), participants were recruited through community
advertisements. We utilized a quota-bin sampling technique, balanced for gender,
which allowed for sufficient representation of the expected range of ecstasy use
(bin 15 no use, see below; bin 251–60 tablets; bin 3561–200 tablets; bin
45.200 tablets). Due to heavy comorbid polydrug use among the ecstasy users,
especially marijuana use, bin 1 included marijuana (MJ) users who had never used
ecstasy. Bin 1 assessed a similar range of MJ use as demonstrated by ecstasy users
(ranged from low to very heavy use). Therefore, the combination of all bins
represented the full range of lifetime ecstasy use (from none to heavy), and data
were analyzed using a continuous variable reflecting lifetime or past year ecstasy
exposure. This analytic approach was chosen to closely examine the dose-
dependent relationship across the full range of ecstasy usage while controlling for
polydrug use (especially alcohol and marijuana).
Participants were recruited through community advertisements and screened
by phone to assess eligibility. Eligibility criteria included ages 18–35, being fluent
in English, having maintained abstinence from ecstasy and other substances for at
least 7 days prior to the testing session, and reporting a lifetime ecstasy
consumption level that fell into one of the open sampling bins. Axis I disorders
(psychotic disorder, bipolar disorder, major depressive disorder, or anxiety
disorder) were screened utilizing a modified SCID I/P interview based on DSM-IV
criteria [64]. Interested participants who had positive responses to the screening
questions were discussed in committee; if clear decisions could not be reached
then they were re-contacted and administered the appropriate SCID I/P module
by a trained interviewer. Individuals who met current diagnostic criteria for the
aforementioned disorders (independent of their substance use) were excluded
from the study. Participants were also excluded for a history of traumatic brain
injury or other neurologic or major medical disorders, current psychiatric
medications, or intellectual deficiency or learning disability.
Participants completed a brief background questionnaire, psychological
questionnaires, and were administered a drug use interview and neuropsycho-
logical battery. Upon completion of the study, they were paid $35 and given
informational pamphlets and drug and alcohol treatment referrals. A total of 48
(22 females, 26 males) ecstasy users and 17 MJ (8 males, 9 females) users
completed the study.
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Frequency/Quantity of Drug Use
A modified version [20,51] of the Time-Line Follow-Back [65] technique was
conducted, using memory cues like holidays and personal events to measure past
year drug use. The Time-Line Follow-Back has demonstrated both high test-retest
reliability as well as significant correlation with urine toxicology results [66]. In
addition, a semi-structured interview was used to measure frequency of lifetime
drug use, in which average weekly use for each year a substance was used was
discussed in the context of memory cues such as developmental milestones, school
grades, and relationships [20,51]. For both self- report interviews, the following
drug categories were assessed: ecstasy, marijuana, alcohol, sedatives (barbiturates,
Valium, Xanax, Ativan, ketamine, GHB), stimulants (cocaine, crack cocaine,
amphetamine, and methamphetamine), hallucinogens (PCP, LSD, peoyote,
mushrooms), opioids (heroin, opium), and inhalants (paint, glue, household
cleaners, nitrous oxide, gas). The unit of measure was the self-reported number of
standard units of substances used (tablets for ecstasy; standard drinks for alcohol;
joints for marijuana; grams for stimulants; number of hits for inhalants,
hallucinogens, and opioids; and pills or hits for sedatives).
Family History of Substance Use Disorders (SUD)
Family history of SUD was obtained through a phone interview and positive
status was given if any first or second-degree family member demonstrated at least
one symptom of a known significant SUD (i.e., was diagnosed, received treatment,
had relationships problems due to their use, had significant health problems due
to their use).
Ecstasy Use Patterns
The Ecstasy Survey [20,51] is a self-report instrument that measures ecstasy use
patterns. Age of onset, how frequently ecstasy is simultaneously used with other
drugs, maximum tablet consumption, subjective effects, and beliefs about the
hazards of ecstasy use was measured utilizing a multiple-choice format.
Verbal Memory
The California Verbal Learning Test-2
nd Edition (CVLT-20 [67] was administered
as part of a larger neuropsychological battery (see Medina et al. [20] for
information about other cognitive domains). In this list-learning task, participants
are read 20 words belonging to four semantic categories and asked to recall as
many as possible across five learning trials. They are then read a 20-word
distracter list and asked to recall the second list and then the first list. After this
short delay, they are asked to recall the first list given cues about semantic
categories. After a 20-minute delay, free recall and cued recall are measured.
Following long-delayed recalls, recognition ability is measured. Nine CVLT-2
variables reflecting components of verbal memory were chosen: immediate recall
(including trial 1 recall and recall for the interference list), short delayed recall
(including free and cued recalls), long delayed recall (including free and cued
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correct inclusion of target items and exclusion of intrusion items for both recall
measures), and recognition.
Data Analysis
In order to examine potential confounding variables associated with ecstasy use,
ANOVAs, chi-squares and Kruskal-Wallis tests were run on demographic and
drug use variables to examine differences between ecstasy polydrug users and MJ
users. Data was analyzed to determine whether the assumptions of multiple
regressions were met. Analysis of histogram data revealed that past year ecstasy
and other drug use were skewed to the right. As such, each drug use variable was
log transformed to achieve normal distribution. However, the regression model
was unable to support analysis with all log transformed drug use variables
included. Further, prior literature has shown past year ecstasy use (raw) to be the
most robust predictor of verbal memory, and the quota sampling technique
utilized in recruitment and study inclusion yielded multiple bins of ecstasy
exposure [20]. Additionally, ordinary least squares regression is very robust to
non-normality in predictors so long as all dependent variables are normally
distributed, which was confirmed upon review of histograms. Because of these
issues, non-transformed past year drug use variables were included in the analyses
below. Further, we conducted analysis of all DFBETAS for each case and
regression coefficient. Based on Cohen and colleagues [68] a cut-off of score
of.248 (N565) was utilized. All regression coefficients for every individual were
well below this cut-off; in other words, none of the cases demonstrated significant
influence for any of the predictors. Therefore, all participants were included in the
regression analyses. Given the possible intercorrelations among the drug use
variables, multicollinearity indices were closely examined through inspection of
tolerance and VIF in regression models (e.g., relative reductions in tolerance and
VIF .2.0). This resulted in the exclusion of past year hallucinogen and sedative
usage (which were highly correlated with ecstasy use). All other drug use
categories were included.
The primary analyses included a series of ordinary least squares multiple
regressions that tested whether past year ecstasy exposure (number of tablets) or
an interaction between ecstasy use and gender significantly predicted the CVLT-2
components of verbal memory after controlling for gender, ethnicity, WRAT 3
Reading [69] (which also reflects quality of education, see Manly [70]), family
history of SUD, and frequency of other drug use (alcohol, marijuana, opioids,
inhalants, and sedatives) within the entire sample of polydrug users. Because the
CVLT-II is normed on age and gender only, ethnicity and reading ability were
included in these analyses. In addition, the authors assessed regression findings
within ecstasy users only, in order to compare results with that of the full range of
ecstasy use among polydrug users (including non-use among MJ-using controls).
Interpretations about statistical significance were made if p,.05.
Ecstasy, Verbal Memory & Gender
PLOS ONE | DOI:10.1371/journal.pone.0115645 December 29, 2014 6/2 1Finally, it is important to note that the purpose of this examination was to
assess several components of verbal memory, and this required multiple analyses.
Because corrections for multiple comparisons, such as Bonferroni correction, tend
to increase the likelihood of Type II error, the authors consulted with literature in
this area [71–72]. Thus, the following results are presented without correction,
and findings should be interpreted in this context.
Results
Demographic Information
As previously stated, data from ecstasy and marijuana users were combined in
order to examine ecstasy use as a continuous variable. However, to test whether
there were differences between ecstasy users and MJ users on demographic
variables, ANOVAs and chi-squares were run. There were no significant
differences between the ecstasy users and MJ users in length of education
[F51.5(1, 64), p,.20], verbal ability [F5.03(1, 64), p,.80], or age [F5.35(1, 64),
p,.60]. There was no difference in gender composition of groups [x
2(4)5.25,
p,.61]. However, there was a significant difference in ethnic identification
between groups, with a greater percentage of MJ users identifying as African
American, which reflects the general ethnic distribution of the recruitment region
[x
2(4)511.64, p,.02]. (See Table 1.)
Drug Use Information
On average, ecstasy users had been abstinent from all drugs for 15 days (M515
days, SD517, range 57–117 days) and MJ users had been abstinent for one
month (M531 days, SD589, range 57–378 days). Marijuana was the most
recently used drug for the majority of participants. Ecstasy users had been
abstinent from ecstasy for slightly more than five months on average (M5161
days, SD5128, range 511–491 days), and men and women did not differ in
length of abstinence from ecstasy [F5.00(1, 46), p5.96]. Male ecstasy users
reported simultaneously using alcohol with ecstasy significantly more than females
[F55.98(1, 46), p,.02]. Table 2 provides a detailed description of the type and
quantity of drug use during the past year by group and gender.
Kruskal-Wallis tests were conducted to evaluate differences in past year drug
use between the four groups (male ecstasy users, female ecstasy users, male MJ
users, and female MJ users). Follow-up tests (Holm’s sequential Bonferroni
approach) were conducted to evaluate pairwise differences controlling for Type I
error. Ecstasy users (both male and female) had significantly greater past year
ecstasy (p5.00), sedative (p5.01), and mushroom (p5.00) uses compared to male
and female MJ users. Ecstasy users also had significantly more past year cocaine
use compared to female MJ users (p5.05). Finally, female ecstasy users had
significantly greater methamphetamine use compared to all other groups (p5.03).
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Demographic Variable Ecstasy Users (N548) MJ Users (N517) Chi-Square
Ethnic Identification % Men % Women % Men % Women p,.02
Asian American 3.8 0 0 0
African American 7.7 13.6 62.5 22.2
Hispanic 0 0 12.5 0
Caucasian 76.9 86.4 25 66.7
Native American 0 0 0 0
Other 11.5 0 0 11.1
% % Chi-Square
Gender (men) 54% 47% p,.61
Family History (positive) 52% 53% p,.95
M Range M Range ANOVA
Education (years) 13 10–16 12.5 9–16 p,.22
Reading Ability 105.4 83–118 105.9 83–123 p,.86
Age 23.2 18–35 22.5 18–31 p,.56
doi:10.1371/journal.pone.0115645.t001
Table 2. Past Year Quantity of Drug Use (in Standard Units) According to Group and Gender.
Ecstasy Users (N548) MJ Users (N517)
Males (N526) Females (N522) Males (N58) Females (N59)
Kruskal-
Wallis
Drugs M (N) SD Range M (N) SD Range M (N) SD Range M (N) SD Range p
Ecstasy 17 (26) 21 1–89 12 (22) 24 1–116 0 0 0 0 0 0 .00a
Alcohol 564
(25)
534 20–1836 244
(20)
204 14–662 296
(8)
297 2–906 356
(9)
537 8–1254 .13
Marijuana 603
(24)
910 1–3650 386
(20)
739 1–3185 306
(8)
189 7–608 256
(9)
262 5–728 .50
Opioids* 29 (7) 60 1–164 4 (3) 1 3–5 0 0 0 0 0 0 .12
Cocaine 21 (13) 31 1–110 2 (11) 3 1–8 54 (2) 70 4–103 0 0 0 .05c
Methamph. 5 (4) 9 1–18 10 (8) 23 1–67 0 0 0 0 0 0 .03b
Sedatives
{ 21 (15) 43 2–150 14 (10) 17 1–51 0 0 0 2 (1) 0 2 .01a
LSD/PCP 5 (7) 6 1–18 2 (7) 2 1–5 0 0 0 0 0 0 .10
Mushrooms 10 (16) 22 1–91 3 (8) 4 1–12 0 0 0 0 0 0 .00a
Inhalants 15 (16) 30 1–104 10 (5) 5 5–18 0 0 0 0 0 0 .15
Mean quantities were calculated only for participants who reported using the specific drug at least one time in the past year.
*Includes heroin and opioids.
{Includes GHB, ketamine, barbiturates, ‘downers,’ Valium, Xanax, and Ativan. Methamph 5 methamphetamine. a5 Ecstasy users . MJ users, b5 Ecstasy
females . all other groups, c5 Ecstasy users . MJ females.
doi:10.1371/journal.pone.0115645.t002
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Verbal Memory Functioning
For descriptive purposes, Table 3 provides the means, standard deviations, and
ranges for the CVLT-2 z-scores. ANOVAs were run to examine the difference in
mean z-score between ecstasy and marijuana users as a whole and by gender for
each CVLT-2 variable. Qualitatively, with the exception of trial B, male and female
ecstasy users performed worse than MJ users on each CVLT-2 variable
(between.04 and.86 standard deviations lower).
Bivariate Relationships
See Table 4 for the significant bivariate relationships (Pearson product moment
correlations) between the verbal memory variables and ecstasy and other drug
usage variables (past year). Increased past year ecstasy use was significantly
associated with poorer performance on all of the verbal memory variables except
trial B performance (interference list). As previously stated, past year ecstasy use
was used in the analyses because it was the most robust predictor of cognitive
functioning in previous studies [20].
Multivariate Relationships
Past Year Ecstasy Use & Verbal Memory: Full range of ecstasy use
After statistically controlling for past year consumption of other drugs and
potential confounding demographic variables (gender, ethnicity, reading ability,
family history of SUD), increased past year ecstasy use was associated with poorer
short delayed free [beta 52.31, p,.02] and cued recall [beta 52.33, p,.02], long
Table 4. Simple Relationships between Components of Verbal Memory and Drug Usage Variables (Past Year).
Trial 1 Trial B SDFR SDCR LDFR LDCR
LDFR vs.
SDFR Recall Disc. Recog.
Ecstasy 2.26* 2.19 2.26* 2.39* 2.40* 2.33** 2.28* 2.37** 2.32**
Alcohol .16 .10 2.12 2.17 .01 2.07 .16 2.11 2.25*
Marijuana 2.23 2.05 .05 2.22 .07 2.05 .04 .01 2.28*
Stimulants .08 2.05 2.17 .05 .05 .07 .36* 2.10 2.16
Opioids .06 2.21 2.14 2.17 2.13 2.06 2.08 2.12 2.07
Sedatives 0.00 2.25* 2.11 2.28* 2.16 2.16 2.10 2.15 2.11
Hallucinogens 2.13 2.27* 2.22 2.34** 2.18 2.25* .01 2.22 2.24
Inhalants .08 .12 2.20 2.01 2.04 .01 .20 .01 2.01
Correlations are Pearson Product Moment Correlations. Abbreviations: SDFR 5 Short Delay Free Recall, SDCR 5 Short Delay Cued Recall, LDFR 5 Long
Delay Free Recall, LDCR 5 Long Delay Cued Recall, LDFR vs. SDFR 5 Long Delay Free Recall vs. Short Delay Free Recall, Recall Disc. 5 Recall
discriminability, Recog. 5 Total recognition.
*p,.05.
**p,.01.
doi:10.1371/journal.pone.0115645.t004
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between long and short delays [beta 52.26, p,.04], recall discriminability [beta
52.34, p,.01]. Past year ecstasy use did not predict trial 1 recall [beta 52.17,
p,.24] or trial B recall [beta 52.23, p,.14]. Past year ecstasy use interacted with
gender in significantly predicting retention between long and short delays [beta
5.35, p,.003]; male ecstasy users demonstrated a more robust relationship
between increased past year ecstasy use and poorer verbal memory performance
compared to female users (see Fig. 1).
Past Year Ecstasy Use & Verbal Memory: Ecstasy users only
Among ecstasy users only, all significant predictions of past year ecstasy use were
consistent with those reported in the full sample, with the exception of long delay
cued recall and retention [beta 52.01, p5.14; beta 52.01, p5.46, respectively].
As before, the significant interaction between increased past year ecstasy use and
gender predicted retention in the same direction [beta 5.02, p5.009].
Comorbid Drug Use & Verbal Memory
Greater alcohol use was associated with poorer short delay cued recall [beta
52.26, p,.04; not significant in ecstasy only analyses] and recognition ability
[beta 52.28, p,.04; same in ecstasy only analyses]. Increased inhalant use was
associated with poorer short delay free recall [beta 52.26, p,.05]; in ecstasy only
analyses increased inhalant use was still associated with poorer short delay free
recall as well as better retention [beta 5.01, p,05]. Increased stimulant use was
associated with poorer short delay free recall [beta 52.27, p,.05]; in ecstasy only
Fig. 1. Bivariate Relationship between CVLT-2 Retention z-score and Past Year Ecstasy Use According
to Gender.
doi:10.1371/journal.pone.0115645.g001
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recall as well as better retention [beta 5.01, p,01].
Length of abstinence from ecstasy
Pearson correlations were run in the male and female ecstasy users to examine the
relationship between length of abstinence from ecstasy and verbal memory
functioning. As shown in Table 5, the female users (n526) generally demon-
strated improved verbal memory with increased ecstasy abstinence, with
significant positive relationships between ecstasy abstinence and short delayed
cued recall and recognition ability and moderate relationships with immediate
recall, short delay free recall, long delay free and cued recall and recall
discriminability. In contrast, no significant relationships were observed in the
male ecstasy users (n526). Fisher z calculations revealed that females had
significantly more robust relationships between ecstasy abstinence and short delay
cued recall (p,.10) and recognition ability compared to men (p,.05).
Discussion
This study examined whether ecstasy exposure and gender interact in predicting
component processes of verbal memory as measured by a list-learning task in 65
young adult ecstasy polydrug users with a full range of ecstasy exposure (from no
use to heavy) after controlling for comorbid drug use and important demographic
variables including family history of SUD. Increased past year ecstasy use
significantly predicted all but 3 of the 9 CVLT-2 verbal memory components in a
dose-dependent fashion after controlling for polydrug use and potentially
confounding variables. Specifically, this included variables measuring short and
Table 5. Simple Relationships between Components of Verbal Memory and Ecstasy Abstinence by Gender.
Ecstasy Abstinence
Females (n522) Males (n526) Fisher’s z
Trial 1 .36* .03 1.12
Trial B .23 .24 2.03
SDFR .41* .27 .51
SDCR .49** .04 1.6*
LDFR .36* .09 .92
LDCR .41* .08 1.15
LDFR vs. SDFR 2.03 2.20 0.56
Recall Disc. .40* .26 0.51
Recog. .58** 2.04 2.27**
Correlations are Pearson Product Moment Correlations. Fisher’s z statistics were calculated to determine whether correlations were significantly different
between male and female ecstasy users. Abbreviations: SDFR 5 Short Delay Free Recall, SDCR 5 Short Delay Cued Recall, LDFR 5 Long Delay Free
Recall, LDCR 5 Long Delay Cued Recall, LDFR vs. SDFR 5 Long Delay Free Recall vs. Short Delay Free Recall, Recall Disc. 5 Recall discriminability,
Recog. 5 Total recognition.
*p,.10.
**p,.05.
doi:10.1371/journal.pone.0115645.t005
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When the model was examined with only individuals with ecstasy use, increased
use predicted 4 of 9 variables. In addition, male ecstasy users had a particularly
robust relationship between past year ecstasy exposure and retention compared to
female users in both models. Increased alcohol use was independently associated
with poorer short delayed cued recall and recognition; increased inhalant and
stimulant use were independently associated with poorer short delayed free recall.
Finally, increased abstinence from ecstasy was significantly associated with
improved verbal memory functioning in the females, especially in short delay cued
recall and recognition ability.
The primary findings of this study suggest that past year ecstasy consumption
negatively impacts several components of verbal memory (retrieval, retention, and
recall discrimination) for both men and women. In fact, ecstasy users performed,
on average,.60 standard deviations below published norms and.47 standard
deviations below the MJ polydrug controls. These are clinically significant
differences for several reasons: ecstasy polydrug users were otherwise healthy
young adults who had no independent comorbid Axis I disorders (besides
possible ADHD and conduct disorder), no neurological injuries, and had been
abstinent from ecstasy for an average of five months. With few exceptions
[28–30], these results are consistent with much of the literature regarding ecstasy’s
effect on immediate and delayed verbal memory [19,38–43]. However, few
studies have broken down verbal memory into components aside from immediate
versus delayed recall. Quednow et al. [41] examined the relationship between
ecstasy exposure and components of verbal memory (measured by the RAVLT) in
a sample of male ecstasy polydrug users, MJ users, and normal controls. Although
they found reduced immediate and delayed recall, they reported spared cued recall
and recognition ability. This discrepancy may have been due to differences in
extent of ecstasy exposure, polydrug use patterns and statistical power. For
example, Halpern and colleagues [29] reported intact verbal memory functioning
in a sample of ecstasy users who demonstrated less lifetime exposure, but most
notably also had substantially less lifetime alcohol, marijuana and other illicit drug
use and all users were abstinent from marijuana. Although the current study
statistically controlled for comorbid drug use (with the exception of hallucinogens
and sedatives), our ecstasy users were generally heavier drug users and may have
also engaged in more simultaneous drug use, although Halpern and colleagues did
not report the latter. Therefore, the current findings provide further evidence that
increased ecstasy use, within the context of polydrug use, is associated with verbal
memory deficits.
Potential combined drug use may have also contributed to our gender findings.
The current study found that male ecstasy users were more likely to take ecstasy
simultaneously with alcohol compared to female users (p,.02), who were more
likely to use ecstasy alone with no other substances. While there is some research
supporting possible neuroprotective effects of simultaneous substance use [73], at
least one study found that binge ethanol administration prior to MDMA exposure
increased the neurotoxic effects of MDMA in the hippocampus in rats, regardless
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with increased body temperature) [74]. Additional research in humans is needed
to examine the effects of simultaneous use of ecstasy and other substances,
particularly alcohol and marijuana, on neurocognitive functioning.
Results suggest that male ecstasy users exhibit a more robust relationship
between ecstasy exposure and poorer performance on retention, with a trend
towards poorer retrieval of information, especially following a long delay. This
result is consistent with Bolla et al. [61], as male users performed more poorly
than female users in a dose-dependent relationship on delayed recall and measures
of retention. Given these findings, ecstasy use may reduce neurogenesis in the
hippocampus through its impact on the serotonin system, most especially in
males [21–22,75–82]. This is in contrast with Reneman et al. [60], who noted
increased sensitivity of the serotonin system in female ecstasy users as reflected by
reduced number serotonin transporters. However, females demonstrated an
increased number of transporters following one year of abstinence. Perhaps
females are more susceptible to serotonergic neurotoxicity during use, but
demonstrate an increased ability to recover following abstinence. Indeed, our
current data support this hypothesis, at least within the constraints of a cross-
sectional design. Compared to the males, female ecstasy users in the current study
demonstrated a significantly more robust relationship between increased ecstasy
abstinence and improved short delay cued recall and recognition ability. It is
worth noting that such differential gender findings may be related to the
composition of the each gender group. Table 2 lists past year quantity of drug use
only for those individuals who endorsed use. In the ecstasy group, men
demonstrated increased polydrug use compared to women, especially for
mushroom and inhalant use; conversely, female ecstasy users reported greater
meth use than male ecstasy users. While these differences were not statistically
significant, they do suggest relatively increased polydrug use patterns among
males and may help explain our gender differences findings. Future longitudinal
research will be necessary to confirm the differential trajectories in recovery
between male and female ecstasy users, with the consideration and analysis of
patterns of polydrug use behavior.
Potential limitations of the current study need to be considered. First, there is
no control group for comparison to the drug-using group. However, we
specifically modeled the groups to assess for the unique contribution of ecstasy
dose within typical polydrug users (with and without ecstasy use). We believe that
these findings are still clinically and statistically meaningful given the dose-
dependent pattern of deficits as well as the poorer performance relative to
published norms. In addition, there may be additional limitations related to the
variation in ecstasy use among the entire sample. As mentioned in the data
analysis section, we chose to include raw past year drug use and examine the full
range of past year ecstasy use (including none) in the regression as ordinary least
squares regression is very robust to non-normality in predictors when DVs are
normally distributed. However, there is evidence that the strength of some
relationships, specifically 2 of the components that were significant in the full
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may demonstrate that results are optimally robust when the full range of ecstasy
use (including none); reduced power when removing 35% of the sample should
also be considered. Of note, an examination of scatterplots suggested two ecstasy
users (one male with 89 past year uses and one female with 116 past year uses)
were outliers in their past year ecstasy use. Although these two may appear to be
outliers in their ecstasy use, they were purposely sampled for in order to examine
dose-dependent relationships; hence, we were more concerned about whether or
not these cases demonstrated undue influence on each ecstasy and ecstasy-by-
gender regression coefficients when predicting the verbal memory variables.
Analyses revealed that all DFBETAS were ,.248, the recommended cut off given
our sample size [68]. Therefore, we did not exclude any participants from the
analysis based on their ecstasy exposure. Second, as mentioned earlier, ecstasy
users were more likely to use cocaine, sedatives, methamphetamine and
mushrooms than MJ users. Although polydrug use was controlled for in analyses,
issues related to multicollinearity required inability to control for hallucinogen
and sedative use in regression analyses, and our findings must be interpreted
within the context of polydrug use. Indeed, Daumann and colleagues [83] noted
brain activation differences between pure and polydrug ecstasy users during a
working memory task, and authors suggested that polydrug use in the sample may
have modified the findings associated with ecstasy use alone. As mentioned
earlier, the present findings did not undergo correction for multiple comparisons
due to the nature of the study of components of verbal memory as well as the
tendency for increased Type II errors in such conservative corrections (e.g.,
Bonferroni). However, the authors noted that some of our findings survived a less
conservative alpha criterion of 1%, for the prediction of ecstasy use on long delay
free (p,.001), recall discriminability (p,.01), and the interaction with gender on
retention (p,.003; for the analysis with the full range of ecstasy use). In addition,
the amount of MDMA in the ecstasy tablets consumed by participants was
unknown, and thus it is important to note that the dose-dependent effects
reported in this study were related to what participants considered ‘‘ecstasy,’’
which typically contains primarily MDMA but may also contain other substances
such as MDA (methylenedioxyamphetamine), ephedrine, caffeine, DXM
(dextromethorphan), ketamine, PMA (paramethoxyamphetamine), cocaine and
methamphetamine.
Another limitation to this study was that participants were not required to
submit to a drug toxicology test to assess for current intoxication and to
corroborate self-reported recency of drug use. Unfortunately, one testing session
would not have captured the length of abstinence from ecstasy required (7 days),
as MDMA is typically out of the user’s system within 2–4 days. On the other hand,
there is a lengthy detection window for THC captured by traditional urinalysis
(from several days to several weeks), meaning that it would be likely that regular-
using individuals reporting at least 7 days of abstinence would still have THC in
their systems. As such, at least 2 toxicology sessions to confirm abstinence would
have been ideal. Thus, use within the 7-day abstinence period cannot be ruled out
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to maximize the reliability of users’ self-reports. This included expressed
confidentiality, privacy, and double assessment of length of abstinence. The Time
Line Follow-Back technique was employed, which has demonstrated high re-test
reliability and convergent and discriminant validity compared to other established
measures, high agreement with collateral informants and patient’s urine assays
[66]. In fact, a recent meta-analysis reported high agreement (nearly 90%)
between Time Line Follow-Back self-report and biological assays across 29 studies
[84]. Future studies should require at least 2 toxicology screenings, with advanced
testing assessing THC metabolites, to confirm self-reported abstinence as well as
sobriety on session day. In addition, we did not measure the proportion of ecstasy
ingested relative to body weight; it is possible women may have had greater
exposure because of lower average body weight and increased body fat percentage,
although this hypothesis do not explain the poorer performance in the men given
similar ecstasy use across genders. Risk factors associated with drug use, including
family history of SUD, conduct disorder and attention deficit hyperactivity
disorder (ADHD) are themselves related to cognitive function and diagnoses can
differ by gender [85–86]. It is notable that the current study did exclude for
independent psychiatric mood, anxiety, and psychotic disorders, and we
statistically controlled for family history of SUD, which was not a significant
predictor in any of the models; still, individuals with conduct disorder and ADHD
were not excluded. Therefore, further research is necessary to disentangle the
potential effects of these premorbid factors.
In conclusion, we found that increased ecstasy exposure was associated with
nearly every component of verbal memory assessed, including proactive
interference, delayed memory, retention of previously learned information,
reduced discrimination ability, and poorer recognition. Such deficits were notable
in a sample of physically healthy young adults without a history of psychiatric or
neurological disorders, even after controlling for comorbid drug use and
important demographic variables (including family history of SUD). In addition,
male ecstasy users were more vulnerable to deficits in retention following a long
delay compared to female users. Results highlight the considerable deficits in
verbal memory associated with ecstasy consumption among both men and
women who engage in polydrug use, even among recreational users (1–2 tablets
per month on average). Future studies are needed to determine underlying
etiology of this gender difference in verbal memory long delay retention.
Given the observed deficits in verbal memory, an examination of possible
recovery of function with greater prolonged abstinence from ecstasy [87] and
treatment programs aimed at improving cognitive functioning (e.g., exercise,
cognitive rehabilitation) are needed. Studies aimed at determining individual
differences in neurocognitive consequences of ecstasy use in young adults are also
needed. Potential targets include different patterns of drug use- such as
simultaneous ecstasy and binge drinking patterns [74], body mass index [88],
extent of physical activity [89], and variability in genes regulating growth factors
or serotonin functioning such as BDNF [90–92]o r5-HTTLPR [93].
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